SNSS Sunesis Pharmaceuticals Inc.

0.56
-0.01  -2%
Previous Close 0.57
Open 0.58
Price To Book 3.1
Market Cap 62,038,636
Shares 111,320,000
Volume 2,808,790
Short Ratio
Av. Daily Volume 2,384,191
Stock charts supplied by TradingView

NewsSee all news

  1. Sunesis Pharmaceuticals Announces Data from Ongoing Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies

    SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced data from the Company's Phase 1b/2 clinical trial of its non-covalent BTK inhibitor

  2. Sunesis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Highlights

    Phase 1b/2 Trial of Vecabrutinib in 400 mg Cohort; Clinical Update at Upcoming ASH Annual Meeting  Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE

  3. Sunesis Pharmaceuticals to Present at 28th Annual Credit Suisse Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate

  4. Sunesis Pharmaceuticals Announces Presentation at 61st American Society of Hematology Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced a poster presentation at the 61st American Society of Hematology (ASH) Annual Meeting to be

  5. Sunesis Pharmaceuticals Appoints Dr. Nicole Onetto to the Board of Directors

    SOUTH SAN FRANCISCO, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Dr. Nicole Onetto, M.D. has been appointed to the Sunesis Board of Directors. Dr. Onetto

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 data to be presented at ASH December 8, 2019 showed 7/15 stable disease, zero partial responses. Phase 2 trial to be initiated 1H 2020.
Vecabrutinib (SNS-062)
Advanced B-Cell Malignancies
Endpoint not met Oct 2014. Additional trials required.
Voreloxin
Cancer - Acute myeloid leukemia AML

Latest News

  1. Sunesis Pharmaceuticals Announces Data from Ongoing Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies

    SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced data from the Company's Phase 1b/2 clinical trial of its non-covalent BTK inhibitor

  2. Sunesis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Highlights

    Phase 1b/2 Trial of Vecabrutinib in 400 mg Cohort; Clinical Update at Upcoming ASH Annual Meeting  Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE

  3. Sunesis Pharmaceuticals to Present at 28th Annual Credit Suisse Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate

  4. Sunesis Pharmaceuticals Announces Presentation at 61st American Society of Hematology Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced a poster presentation at the 61st American Society of Hematology (ASH) Annual Meeting to be

  5. Sunesis Pharmaceuticals Appoints Dr. Nicole Onetto to the Board of Directors

    SOUTH SAN FRANCISCO, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Dr. Nicole Onetto, M.D. has been appointed to the Sunesis Board of Directors. Dr. Onetto

  6. Sunesis Pharmaceuticals to Present at the Wells Fargo Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President of Finance and Corporate